Evidence map›Paper›PMID 40564413›Full record

ArticleBioengineering (Basel, Switzerland)2025

Variable Selection for Multivariate Failure Time Data via Regularized Sparse-Input Neural Network.

Bin Luo, Susan Halabi

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bin LuoSchool of Data Science and Analytics, Kennesaw State University, Kennesaw, GA 30144, USA.ORCID 0000-0002-3983-5676
Susan HalabiDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-4135-2777

Funding

Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCR01CA256157 · NCI · DUKE UNIVERSITY · PI ARMSTRONG, ANDREW J, DEHM, SCOTT M. · 2020 to 2025
$3.2M
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate CancerR01CA249279 · NCI · UNIVERSITY OF MINNESOTA · PI HALABI, SUSAN, SHARIFI, NIMA · 2021 to 2024
$2.1M
Statistical Methods and Validation Analyses for the Integration of External Data in Clinical TrialsR01LM013352 · NLM · DANA-FARBER CANCER INST · PI TRIPPA, LORENZO · 2021 to 2024
$1.5M
Sieve based full likelihood approach for the Cox proportional hazards model with applications to immunotherapies trialsR21CA263950 · NCI · DUKE UNIVERSITY · PI HALABI, SUSAN, WU, YUAN · 2023 to 2024
$405k
FDA HHS U01 FD007857NCI NIH HHS R01 CA249279NCI NIH HHS R01 CA256157NCI NIH HHS R21 CA263950NIH HHS 1R01LM013352-05NLM NIH HHS R01 LM013352
6 · The paper itself

Abstract

This study addresses the problem of simultaneous variable selection and model estimation in multivariate failure time data, a common challenge in clinical trials with multiple correlated time-to-event endpoints. We propose a unified framework that identifies predictors shared across outcomes, applicable to both low- and high-dimensional settings. For linear marginal hazard models, we develop a penalized pseudo-partial likelihood approach with a group LASSO-type penalty applied to the ℓ2 norms of coefficients corresponding to the same covariates across marginal hazard functions. To capture potential nonlinear effects, we further extend the approach to a sparse-input neural network model with structured group penalties on input-layer weights. Both methods are optimized using a composite gradient descent algorithm combining standard gradient steps with proximal updates. Simulation studies demonstrate that the proposed methods yield superior variable selection and predictive performance compared to traditional and outcome-specific approaches, while remaining robust to violations of the common predictor assumption. In an application to advanced prostate cancer data, the framework identifies both established clinical factors and potentially novel prognostic single-nucleotide polymorphisms for overall and progression-free survival. This work provides a flexible and robust tool for analyzing complex multivariate survival data, with potential utility in prognostic modeling and personalized medicine.

Indexed as

group LASSOhigh dimensionalitymultivariate failure timenon-convex penaltyvariable selection

Identifiers

PMID40564413
PMCPMC12189315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.